HIF1A and neoplasm: In tumor-bearing mice administered CaLac by daily subcutaneous injection for 3 weeks, a decrease in tumor volume including the HIF1-α and VEGF deactivation, and suppression of liver metastasis were confirmed (Figure 6 and Figure 7).